A study conducted by Jerome Hadjadj, MD, PhD, and colleagues found that among targeted therapies, patients with VEXAS syndrome responded most overall to JAK inhibitors and IL-6 blockers. The study included 110 adults with VEXAS syndrome who received different targeted therapies, with JAK inhibitors showing the longest survival without treatment discontinuation. The researchers noted that there is currently no standardized therapeutic strategy for VEXAS syndrome and called for prospective studies to further examine the safety and efficacy of targeted therapies. The study confirmed the benefit of JAK inhibitors and IL-6 inhibitors, while IL-1 and TNF blockers were found to be less effective.
Source link
JAK, IL-6 inhibition most effective targeted therapies for VEXAS syndrome
